MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Thursday, March 28, 2013

Now approved—a new pill for relapsing forms of multiple sclerosis (MS)

New and now FDA approved! Tecfidera TM (dimethyl fumarate), also known as BG-12.


Tecfidera was approved by the FDA for the treatment of people with relapsing forms of MS.



Taking Tecfidera

What you need to know before you start treatment.
Learn more here. »



Important Safety Information
Please see the full Prescribing Information and Patient Information for additional important safety information. This information is not intended to replace discussions with your doctor.

Learn More- Click here: http://www.tecfidera.com/ 


==========================


USE OUR SHARE LINKS at the top of this page  - to provide this article to others

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left

REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register


.

No comments: